ResearcherSichuan UniversityActive in the last 2 years
Huanji Xu
Matched on ORCID iD 0000-0003-0314-5646; OpenAlex author ID A5036650597. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 30
2025: 2 papers · 2026: 3 papers
Papers 5
- Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025). Co-author DOI 10.1038/s41416-026-03522-x↗
- Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy versus gemcitabine and nab-paclitaxel as first-line treatment for rec… Last author DOI 10.3389/fimmu.2026.1817221↗
- Safety and efficacy of the MNK/VEGFR inhibitor JDB153 combined with the anti-PD-1 antibody serplulimab in patients with advanced pancreatic cancer refractory t… Last author DOI 10.3389/fphar.2026.1805590↗
- RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line treatment for metastatic pancreatic adenocar… Co-author DOI 10.21203/rs.3.rs-7291840/v1↗
- HRS-4642 combined with nimotuzumab in the treatment of recurrent or metastatic pancreatic ductal adenocarcinoma: study protocol of a single-arm, prospective ph… Co-author DOI 10.3389/fphar.2025.1562481↗
Closest collaborators
The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dan Cao · 4 shared papers, 2025–2026 · strength 1.25
- Paper Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy versus gemcitabine and nab-pa… DOI 10.3389/fimmu.2026.1817221↗
- Paper Safety and efficacy of the MNK/VEGFR inhibitor JDB153 combined with the anti-PD-1 antibody serplulimab in patients with… DOI 10.3389/fphar.2026.1805590↗
- Paper Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025). DOI 10.1038/s41416-026-03522-x↗
- Xiaorui Zhu · 2 shared papers, 2025–2026 · strength 0.59
- Paper Safety and efficacy of the MNK/VEGFR inhibitor JDB153 combined with the anti-PD-1 antibody serplulimab in patients with… DOI 10.3389/fphar.2026.1805590↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Qingqing Leng · 2 shared papers, 2025 · strength 0.47
- Paper HRS-4642 combined with nimotuzumab in the treatment of recurrent or metastatic pancreatic ductal adenocarcinoma: study … DOI 10.3389/fphar.2025.1562481↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Xin Wang · 1 shared paper, 2026 · strength 0.43
- Ke Cheng · 2 shared papers, 2025–2026 · strength 0.39
- Dan Cao · 1 shared paper, 2025 · strength 0.30
- Xin Wang · 1 shared paper, 2025 · strength 0.30
- Wei Li · 1 shared paper, 2026 · strength 0.23
- Chunyi Hao · 1 shared paper, 2026 · strength 0.23
- Haitao Zhang · 1 shared paper, 2026 · strength 0.23
- Guang Tan · 1 shared paper, 2026 · strength 0.23
- Liwei Wang · 1 shared paper, 2026 · strength 0.23
- Jianhui Wu · 1 shared paper, 2026 · strength 0.23
- Jiujie Cui · 1 shared paper, 2026 · strength 0.23
- Kuirong Jiang · 1 shared paper, 2026 · strength 0.23
- Qi Li · 1 shared paper, 2026 · strength 0.23
- Guanghai Dai · 1 shared paper, 2026 · strength 0.23
- Shukui Qin · 1 shared paper, 2026 · strength 0.23
- Chengjian Zhao · 1 shared paper, 2025 · strength 0.16
- Xiaoying Li · 1 shared paper, 2025 · strength 0.16
- Zixing Huang · 1 shared paper, 2025 · strength 0.16
- Chen Chang · 1 shared paper, 2025 · strength 0.16
- Yi Zhang · 1 shared paper, 2025 · strength 0.16
- Junjie Xiong · 1 shared paper, 2025 · strength 0.16
- Yi Cheng · 1 shared paper, 2025 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.